{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8"],"submitter":["Moady G"],"pubmed_abstract":["Heart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generation of continuous-flow devices, particularly with the fully magnetically levitated HeartMate 3. In June 2021, Medtronic announced the abrupt withdrawal of the HeartWare device from the market. This decision has introduced a new era in which the field of mechanical support for advanced HF patients is dominated by a single device - the HeartMate 3. The direct clinical and economic consequences of this change will necessitate new surgical considerations. Because of the expected need for HeartWare de"],"journal":["Cardiac failure review"],"pagination":["e33"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9820067"],"repository":["biostudies-literature"],"pubmed_title":["Ventricular Assist Devices: Challenges of the One-device Era."],"pmcid":["PMC9820067"],"pubmed_authors":["Moady G","Ben-Avraham B","Atar S","Ben-Gal T"],"additional_accession":[]},"is_claimable":false,"name":"Ventricular Assist Devices: Challenges of the One-device Era.","description":"Heart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generation of continuous-flow devices, particularly with the fully magnetically levitated HeartMate 3. In June 2021, Medtronic announced the abrupt withdrawal of the HeartWare device from the market. This decision has introduced a new era in which the field of mechanical support for advanced HF patients is dominated by a single device - the HeartMate 3. The direct clinical and economic consequences of this change will necessitate new surgical considerations. Because of the expected need for HeartWare de","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-04T14:29:54.534Z","creation":"2025-04-04T14:29:54.534Z"},"accession":"S-EPMC9820067","cross_references":{"pubmed":["36644648"],"doi":["10.15420/cfr.2022.01"]}}